The new edition of the Chinese Pharmacopoeia affects the entire pharmaceutical industry; the important documents of the National Health and Care Commission affect hospital drug use, wave and related pharmaceutical companies; the global vaccine bottle is in short supply, and the production capacity is seriously inadequate...

Guide: "China Pharmacopeia" attracted attention, the pharmaceutical industry turbulence hit!this week to seethe new edition of the Chinese Pharmacopoeia will affect the entire pharmaceutical industry;hospital performance appraisal system is perfect, abuse of god medicine is stripped out;the world's new crown vaccine bottle urgent;the second domestic second-price HPV vaccine report;government newsthe 2020 edition of the Chinese Pharmacopoeia announced, affecting the entire pharmaceutical industryJuly 2, the State Drug Administration, the National Health and Health Administration issued a public notice, officially promulgated the 2020 edition of the People's Republic of ChinaA total of 5911 varieties were collected, an increase of 5.5% compared to the 5608 species of the 2015 edition of the Pharmacopoeianational drug standards are mandatory provisions made by the state to ensure the quality of drugs, guide drug researchers and drug licensing holders to do a good job in drug research and development and quality control after drug market, and to make quality control items, technical indicators, testing methods, etcIt is an important part of the national drug standard and the core of the national drug standard systemthe 2020 edition of the pharmacopeia preparation work to fully implement the "four most stringent" requirements, in line with the law of industrial development, clinical demand-oriented, in a moderate increase in the number of drug collection varieties, reflect the drug life cycle quality management, improve the drug standards system, strengthen the effectiveness of drug safety control, expand the application of mature analysis and testing technology, guide the development of industry and innovation can be enhanced, strengthen coordination with international drug standards and other aspects have made great progresssaid that the promulgation and implementation of the new edition of the Pharmacopoeia will certainly play an important role in ensuring the quality of medicines, safeguarding public health and promoting the high-quality development of the pharmaceutical industrythe National Health and Care Commission important documents affecting hospital drug use, Wave and related pharmaceutical enterprisesJuly 1, the National Health and Care Commission released an important document "on the 2018 national three-level public hospital performance appraisal of the national monitoring and analysis of the relevant information" (hereinafter referred to as "Circular")it is understood that, according to the Opinions of the General Office of the State Council on Strengthening the Performance Evaluation of Three-Level Public Hospitals, 26 performance appraisal monitoring indicators were analyzed in 2019 according to the 2018 data of the National Third-level Public HospitalsThe national monitoring and analysis (Western medicine level III public hospitals) is now communicateddocument shows that the performance appraisal of three-level public hospitals in the entire indicator system, including 4 first-level indicators, 14 secondary indicators, 55 three-level indicators (quantitative 50, qualitative 5)Among them, there are nearly 10 indicators, highly related to the use of drugs in tertiary hospitals, for these indicators, the Health and Health Commission has given a gradual decline or rise of the guiding requirements, including: antimicrobial drug use intensity (DDDs) gradually decreased;this major reform to a certain extent, the clinical drug market has been shaken, the impact on the relevant enterprisesThe effect of the construction of graded diagnosis and treatment system gradually appears, and clinical drug use becomes more reasonableindustry has the view that only by establishing an effective performance appraisal system can we better guide public hospitals towards the desired resultsIn this context, some clinical efficacy is not clear, known as "wanjin oil", abuse of the god drug, will be obviously limited in use, and these performance appraisal indicators will also be the three-level hospital clinical drug use constraintsmarket newsZhejiang: has not been rated generic drug hanging network need to reduce prices!On June 29,, Zhejiang Province issued the "Zhejiang Province to enhance the function of centralized drug procurement platform to promote the standard of medical insurance drug payment full coverage reform program" (hereinafter referred to as the "reform program"), and officially implemented on September 1"Reform program" clearly, for non-conformity evaluation of generic drugs, in order to enter the Zhejiang market, the same dosage type of products on the basis of the lowest price of another 30% or on the basis of the original research drug price slower than halfIn addition, the platform online trading products, the establishment of a market-oriented exit mechanism, through the development of volume procurement, the implementation of small unit with the standard bidding, the formulation of the same list of one medical insurance payment standards and other ways to withdrawa new round of Chinese medicine rectificationJune 28, the State Administration of Traditional Chinese Medicine forwarded the Heilongjiang Provincial Government issued "on the promotion of the development of Innovation in Chinese Medicine", accelerate the promotion of Chinese medicine inheritance and innovation and development work, in addition to improving the Chinese medicine service system, give full play to the characteristics of Chinese medicine, strengthen the construction of Chinese medicine information and other content, focusing on improving the quality of Chinese medicine and promoting the development of the relevant requirementsThis opinion has greatly accelerated the standardization of Chinese medicine standardization progress and the whole chain of Chinese medicine shuffle action, Chinese medicine enterprises face a new round of rectification The State Drug Administration: 9 drugs discontinued, recalled July 2, the State Drug Administration issued Circular No 45 of 2020, informed 10 batches of non-compliant drugs It is pointed out that by Jiangxi Province Drug Inspection and Testing Research Institute and other 9 drug inspection institutions, marked as Chengdu Jinhua Pharmaceutical Co., Ltd and other 10 enterprises produced 10 batches of drugs do not meet the requirements combing found that 10 batches of non-conforming drugs, there are 7 batches of preparations, respectively, pyrethyl amide tablets, Lansoraaintestinal tablets, injection of inflammatory amber (with 2 batches), wood yellow particles, clear-eye, viheinparticles; The State Drug Administration has asked relevant enterprises and units to take risk control measures such as suspension of sales and use, recall, etc., to investigate the reasons for non-compliance and to carry out effective rectification global vaccine bottle emergency, "medium boron silicon glass bottle" production capacity is seriously inadequate
recently, according to relevant media reports around the world has more than 100 teams are competing to develop a new crown vaccine, WHO in the new crown pneumonia routine release revealed that the world has more than 200 candidate vaccines, 15 of which are in human clinical trials the bad news is that the lack of glass vials needed to store the vaccine makes it impossible to roll it out on a global scale immediately, even if it is approved for production "Even the vaccine bottles and filling procedures don't have enough reserves around the world, " said Gates, who was busy fighting the epidemic in the U.S as early as late April John Bell, a professor at Oxford University's School of Medicine, told the BBC that there were only 200m vaccine glass bottles left in the world and that a crisis was in crisis In addition, several vaccine scientists have raised concerns that the lack of a shortage of vaccine glass bottles could affect the global roll-out of the new crown vaccine thanks to the above news, domestic vaccine bottle production enterprises into the investment wind, Shandong medicine glass led by the "boron silicon glass bottle" production capacity of enterprises all-round rise and fall, in addition to Qibin Group, Deli shares and other enterprises have also said that they are currently building "medium boron silicon glass bottle" production project, for a time, the global eye again focused on the domestic market "God Drug" Redsewey final pricing announcement! $390 a bottle fell short of Wall Street expectations on June 29, Gilead Sciences announced a price for its new crown drug, Redseve In an open letter, Daniel O'Day, the company's chairman and chief executive, said that in the face of global needs, Gilead had set the price of Redsiwe to developed country governments at $390 a bottle to ensure broad and fair access to drugs based on the current treatment model, the vast majority of patients are expected to receive five days of treatment, which will use six bottles of Ridsivir, which is equivalent to a course of treatment of $2,340 per patient, or about 165,000 yuan At the same time, the price for private insurance companies in the United States will be $520 per bottle, about $3,120 a course of treatment, or about 22,000 yuan enterprise information collection forced the transformation of the four major drugstore chains, diversification development is a trend June 29, head pharmaceutical retail chain set up a single-minded medical service company and obtained a business license, take a step towards diversification and exploration So far, the people, Dasan Lin, One Heart, Yifeng Pharmacy, the four major retail chain pharmacies, most of them in the recent completion of business development exploration or the pace of deep transformation For example, the people to Tencent issued a market value of 600 million shares to raise capital, the two sides "strong and strong alliance", and Yifeng big pharmacy signed a trepco, accelerate digital empowerment and so on in fact, the implementation of the drug centralized procurement policy, including the people's big pharmacy, DasanLin and other drug store chains announced the price reduction of related drugs, to achieve the hospital "same drug price", which has a certain impact on pharmacy profits in this case, the major drugstore layout medical services business to explore new profit points is also helpless, and with the formation of drug price reduction trend, the future drug profits will continue to compress, for the bulk of the pharmaceutical retail chain, the new way out represents may also be a new way Gan Li Pharmaceuticals listed, with a market value of 36.6 billion yuan on June 29, Gan Li Pharmaceuticals listed on the main board of the Shanghai Stock Exchange, the stock code 603087, the issue price of 63.32 yuan, on the same day, Gan Li Pharmaceuticals shares rose 44% from the issue price, reached 91.18 yuan, with a total market value of 36.572 billion yuan In this listing, the company issued 40.2 million shares of RMB common stock, by CITIC Securities, Oriental Securities as co-sponsors the development, production and sales of apire recombinant insulin analogues (third-generation insulin) API, the first Chinese company to master the technology of industrial production of recombinant insulin analogues The company's main business income is mainly insulin preparation income (accounting for more than 95%), of which the restructuring of insulin insulin injection (Long Xiuyu) sales revenue accounted for more than 90% of the main business income, is the company's most important source of income the day of listing, the current market value of Gan Li Pharmaceuticals has exceeded the old owner of "Tonghua Dongbao", love and kill the situation has been initially formed the second domestic two-price HPV vaccine reported July 1, according to the CDE official website, Yuxi Zerun Biotechnology Co., Ltd recombined the human papillomavirus double price (16/18) vaccine (yeast) listing application was accepted, which means that the second domestic second-price hpv vaccine reported, domestic HPV vaccine is expected to usher in a new spoiler HPV vaccine can effectively prevent the onset of cervical cancer and prevent human infection vaccine sepsis of human papillomavirus subtypes At present, a total of four HPV vaccines have been approved for sale worldwide the global HPV vaccine market has been dominated by Both Mercado and GlaxoSmithKline, China's first cervical cancer vaccine, a full 10 years later than europe and the United States It was not until 2020, when the first domestic two-price HPV vaccine, Xinkonin, went on the market, that the monopoly of foreign companies on the domestic HPV market was broken Compared with the import of HPV vaccine, domestic brands have a clear price advantage but related data show that the domestic HPV vaccine market as a whole is in an expanding state, of which the four-valent and nine-valent HPV vaccine dominates, the market for divalent HPV vaccine is shrinking gradually I do not know whether the domestic second-priced HPV vaccine market is a good or bad, can change the current HPV vaccine market pattern, usherin in a new growth space Sanofi, the , announced more than 1,680 people will cut more than 1,680 jobs in Europe to cut costs and boost profits, Reuters reported A spokesman for Sanofi said the cuts would take place within three years, mainly involving blue-collar workers at the plant The future will focus on increasing efficiency through digitalization and IT outsourcing , there are reports that Sanofi is also considering cutting hundreds of staff and holding talks with staff representatives on Friday and June 29 All Sanofi plants will not close, but some research centers have stopped since last year's decision to end the two areas of diabetes and cardiovascular research Kangji Medical is listed on the Hong Kong Stock Exchange today: the share price has surged 86% to hk$32 billion on June 29, Kangji Medical was officially listed on the Hong Kong Stock Exchange under the symbol "09997.HK" The offering was priced at HK$13.88 per share and opened at HK$25.9 per share, up 86.6 per cent from the offering price, with a total of 225 million shares issued and a market capitalisation of HK$32.6 billion as of the date of publication Source: Pharmaceutical Intelligence News, Sina Pharmaceutical News, Cyber Blue, E Pharmaceutical Manager, Pharmaceutical Economics, China Pharmaceutical News, Pharmacy Manager, Oriental Fortune Choice Data, Daily Economic News, Interface News, etc .